We’re innovative thought leaders and determined advocates who partner with visionary organizations to change health care.
We’re innovative thought leaders and determined advocates who partner with visionary organizations to change health care.
We’re innovative thought leaders and determined advocates who partner with visionary organizations to change health care.
Impact Health is a mission-driven health policy and strategic consulting firm dedicated to improving health and well-being for all.
OUR SERVICES
Strategic Planning
Integrate mission-aligned policy expertise and political acumen into planning and executing your goals.
Government Contracting
Track record of success supporting states and municipalities in innovating or launching new programs.
Our proprietary method for tracking, aggregating, and analyzing state policy trends.
If you believe that every American deserves to be healthy and well, contact Impact Health Policy Partners to learn how our expertise can help you achieve your goals.
Policy Hub, managed by Impact Health Policy Partners, is the only comprehensive database of Federal health policy developments, cataloged by over 200 healthcare topics and programs. Regulations, reimbursement, grants, ACA implementation, hearing summaries, CRS Reports, pending legislation – you get it all here, with comprehensive, expert analysis.
House Passes Farm Bill Reauthorization
The House passed the Farm, Food, and National Security Act for Farm Bill reauthorization (fact sheet; text) by a vote of 224-200. In addition to agricultural programs, the Farm Bill authorizes several important federal nutrition programs including the Supplemental Nutrition Assistance Program (SNAP) and rural development programs. The 2018 Farm Bill expired on September 30, 2023, but most of the programs were… (McClurg, May 1, 2026) #Nutrition, #Rural Health
Agency Proposes to Exclude GLP-1 Therapies from 503B Bulks List; Comments due June 29
The Food and Drug Administration (FDA) issued a notice proposing to exclude three widely used GLP-1 therapies – semaglutide, tirzepatide, and liraglutide – from the 503B Bulks List, determining that there is no clinical need for outsourcing facilities to compound these products from bulk drug substances (press release). The proposal reflects FDA’s continued emphasis that compounding from bulk ingredients is… (Colocho, May 1, 2026) #Chronic Diseases, #Food and Drug Administration, #Prescription Drugs